| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
| N_HPV: HPV-infected normal cervix |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer |
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions |
| MSI-H: Microsatellite-high colorectal cancer |
| MSS: Microsatellite stable colorectal cancer |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias |
| LGIN: Low-grade intraepithelial neoplasias |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ |
| IAC: Invasive lung adenocarcinoma |
| MIA: Minimally invasive adenocarcinoma |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia |
| NEOLP: Non-erosive oral lichen planus |
| OSCC: Oral squamous cell carcinoma |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma |
| SCCIS:squamous cell carcinoma in situ |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis |
| PTC: Papillary thyroid cancer |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
| GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00310996 | Cervix | CC | regeneration | 46/2311 | 198/18723 | 1.43e-05 | 2.84e-04 | 46 |
| GO:00713648 | Cervix | CC | cellular response to epidermal growth factor stimulus | 16/2311 | 45/18723 | 5.24e-05 | 7.83e-04 | 16 |
| GO:00420586 | Cervix | CC | regulation of epidermal growth factor receptor signaling pathway | 21/2311 | 73/18723 | 1.36e-04 | 1.67e-03 | 21 |
| GO:19011846 | Cervix | CC | regulation of ERBB signaling pathway | 22/2311 | 79/18723 | 1.61e-04 | 1.93e-03 | 22 |
| GO:00708498 | Cervix | CC | response to epidermal growth factor | 16/2311 | 49/18723 | 1.67e-04 | 1.99e-03 | 16 |
| GO:0042246 | Cervix | CC | tissue regeneration | 19/2311 | 72/18723 | 9.11e-04 | 7.81e-03 | 19 |
| GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
| GO:19011857 | Cervix | CC | negative regulation of ERBB signaling pathway | 10/2311 | 32/18723 | 3.96e-03 | 2.48e-02 | 10 |
| GO:00480084 | Cervix | CC | platelet-derived growth factor receptor signaling pathway | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
| GO:0038127 | Colorectum | AD | ERBB signaling pathway | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:0007173 | Colorectum | AD | epidermal growth factor receptor signaling pathway | 50/3918 | 108/18723 | 3.08e-09 | 2.07e-07 | 50 |
| GO:1901185 | Colorectum | AD | negative regulation of ERBB signaling pathway | 19/3918 | 32/18723 | 2.39e-06 | 6.98e-05 | 19 |
| GO:1901184 | Colorectum | AD | regulation of ERBB signaling pathway | 34/3918 | 79/18723 | 7.46e-06 | 1.82e-04 | 34 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0042058 | Colorectum | AD | regulation of epidermal growth factor receptor signaling pathway | 31/3918 | 73/18723 | 2.56e-05 | 4.89e-04 | 31 |
| GO:0070849 | Colorectum | AD | response to epidermal growth factor | 23/3918 | 49/18723 | 4.18e-05 | 7.37e-04 | 23 |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTPN12 | SNV | Missense_Mutation | | c.824N>G | p.Ser275Cys | p.S275C | Q05209 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTPN12 | SNV | Missense_Mutation | | c.263A>T | p.Tyr88Phe | p.Y88F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| PTPN12 | SNV | Missense_Mutation | | c.824N>T | p.Ser275Phe | p.S275F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTPN12 | SNV | Missense_Mutation | rs766786152 | c.1427N>G | p.Ser476Cys | p.S476C | Q05209 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.91) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PTPN12 | SNV | Missense_Mutation | | c.2063C>T | p.Ala688Val | p.A688V | Q05209 | protein_coding | deleterious(0) | benign(0.368) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PTPN12 | SNV | Missense_Mutation | | c.171N>C | p.Glu57Asp | p.E57D | Q05209 | protein_coding | deleterious(0.04) | benign(0.375) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PTPN12 | insertion | Frame_Shift_Ins | novel | c.1281_1282insA | p.Leu430IlefsTer8 | p.L430Ifs*8 | Q05209 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PTPN12 | insertion | In_Frame_Ins | novel | c.1187_1188insCCAATTCTTTCTGTTTTA | p.Val396_Ser397insGlnPhePheLeuPheTyr | p.V396_S397insQFFLFY | Q05209 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTPN12 | SNV | Missense_Mutation | | c.824C>T | p.Ser275Phe | p.S275F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| PTPN12 | SNV | Missense_Mutation | | c.772G>C | p.Glu258Gln | p.E258Q | Q05209 | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |